Abstract
BackgroundAdoptive cell therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with advanced solid cancer.1-3 However, many T cells among the tumor infiltrating lymphocytes (TIL) are not specific...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
